Correlation Between Intestinal Parasites and Serum Level of Eosinophils and IgE in Individuals With HIV or AIDS

April 17, 2008 updated by: UPECLIN HC FM Botucatu Unesp

Phase 1 Correlation Between Intestinal Parasites and Serum Level of Eosinophils and IgE in Individuals With HIV or AIDS

Correlation between intestinal parasites and serum level of eosinophils and IgE in individuals with HIV or aids attended at clinical hospital of the Botucatu Medical School-UNESP

Study Overview

Status

Completed

Conditions

HIV Infections

Detailed Description

The present study correlates intestinal parasitism and levels of eosonophils and of serum IgEs in patients attended at the C.H. of the School of Medicine - Botucatu/UNESP. Thirty adult patients with AIDS were analyzed in the use of HAART, aged 42 ±11 years, 14 (46.7%) male, excluding those that had used anthelminthics 30 days prior to collection. Socioeconomic questionaires were applied and 3 samples of feces were taken for parasitological exams (TF-test® method) and 5 ml of blood for counting eosinophils (automated hematological counter, Pentra 80, ABX) and IgE doses (equipment BN-100, Dade-Behring). The index of parasites was 10%, with E.nana (3.3%), E.coli (3.3%) and B.hominis (3.3%). Parasitized individuals were from an urban region with complete basic sanitation and good socioeconomic level. Normal eosinphil values were found in all samples and increased IgE values in 1 (33.3%) sample. The index of parasites was low due to good socioeconomic level and disease control. Augmented IgE levels corroborate the literature, which reports an increase characteristic of immune response in the face of parasitic infections in individuals with HIV or AIDS. In conclusion, new studies should be undertaken to evaluate the level of eosinophils associated with cytokines to obtain a better understanding of this correlation.

Study Type

Observational

Enrollment (Actual)

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

primary care clinic

Description

Inclusion Criteria:

HIV or AIDS
age same or superior to 18 years,
both sexes
assisted by the Hospital of the Clinics of Botucatu Medical School-UNESP

Exclusion Criteria:

use of anthelminthic in the period of 30 days antecedents the it dates from collection
individuals that don't have all of the necessary evaluations to the objectives of the study
individuals that abandon the attendance, or that you/they are to death during the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Number of groups / cohorts

Cohorts and Interventions

Group / Cohort
1 , 2 those with HIV

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
all Time Frame: one year	one year

Secondary Outcome Measures

Outcome Measure	Time Frame
all Time Frame: one year	one year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

UPECLIN HC FM Botucatu Unesp

Investigators

Study Chair: Paulo C Pereira, Phd, Botucatu Medical School - UNESP

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2007

Study Completion (Actual)

August 1, 2007

Study Registration Dates

First Submitted

October 18, 2007

First Submitted That Met QC Criteria